Abstract
Objective: Study the effects of COVID-19 on health status and alterations in managing patients with CNS-IDDs. Materials and Methods: A questionnaire-based approach was commenced at the MS and Related Disorders Clinic at Siriraj Hospital in Thailand from March 2021 to December 2021. The data obtained from the questionnaire was subjected to statistical analysis. Results: The study comprised 92 patients with CNS-IDDs, with 72.8% female and a mean age of 44.6±14.0 years. Overall, 67.4% of patients were vaccinated following Thai National guidelines. Only two patients were confirmed to have contracted COVID-19 infection. The most common treatment administered in the 92 CNS-IDD patients was Azathioprine (39.1%), prednisolone (32.6%), then 14.1% each in MMF and Rituximab. Sixty-one patients (66.3%) reported no relapse in the past year and no statistically significant difference among the diseases. The mean self-rated quality of life (QoL) score was 8.0±1.9 before the COVID-19 pandemic then drastically decreasing to 5.4±2.4 during the pandemic period. Overall, 56.5% indicated at least some impact on physical well-being, and 69.6% reported challenges to psychological health. 16.3% postponed or canceled their appointments during the COVID-19 pandemic, and 8.3% transitioned from face-to-face meetings with doctors in the clinic to telemedicine or telephone follow-up. Conclusion: Our study revealed that patients with CNS-IDDs experienced no significant change in relapse and a low incidence of COVID-19 infection. During the pandemic, overall, patients' QoL decreased both physically and psychologically.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.